Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insulet Corporation
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
In an interview with Medtech Insight, Glooko CEO Russ Johannesson outlines the company’s growth opportunities, expansion plans beyond diabetes and financing plans.
Deal Snapshot: Lilly bets $135m on biotech’s preclinical SARM1 inhibitor program, seeing potential in peripheral neuropathy and possibly some bigger targets in neurology like MS and ALS.
Three major insulin pump developers are gearing up to introduce next-generation devices over the coming year, but COVID-19 continues to create uncertainties.
- Medical Devices
- Other Names / Subsidiaries
- Insulet Canada Corporation
- Neighborhood Diabetes
- Neighborhood Holdings, Inc.